s.kuusela

TL2 · Turku

Contributes reviews on supplier material. Based in Turku.

Joined 11 September 2025 · last posted 12d · groups: translators

83 posts, newest first. Showing up to 150.

Why chargeback is not the safety net people assume Replied, post #25 · Sourcing › Payments · 16 Jul 2026 · 17 likes Building on post #24 rather than restating it. The strongest argument against my own position on chargeback, stated as well as I can state it, since nobody else has yet.
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #104 · Devices › Syringes & needles · 12 Jul 2026 · 30 likes Post #101 describes the usual case. This is about the unusual one. Fixed versus detachable needles: insulin syringes usually have fixed needles (no dead volume loss to…
Semaglutide and alcohol: what is actually documented Replied, post #15 · Compounds › Semaglutide · 9 Jul 2026 · 0 likes Semaglutide and alcohol: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #37 · Compounds › Retatrutide · 4 Jul 2026 · 0 likes Quietly grateful for the plain phrasing. Not every thread gets that.
Personal or family history of medullary thyroid carcinoma Replied, post #38 · Safety › Contraindications · 2 Jul 2026 · 9 likes Everything in post #34 holds. The case it does not cover is the one I have. Allergy to the specific compound: true allergy is rare but possible. Any prior allergic…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #95 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 26 likes Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #36 · Analytics › Impurities & related substances · 30 Jun 2026 · 7 likes Deamidation at asparagine or glutamine adds approximately one dalton and frequently produces a close-eluting pair. It is the impurity most likely to be integrated into…
Revisiting: How this community labels and discusses unrefereed work Replied, post #10 · Evidence › Preprints · 28 Jun 2026 · 16 likes Speaking only to community labels as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and…
HbA1c lag and what it can and cannot tell you at eight weeks — one year on Replied, post #14 · Clinical › Bloodwork · 27 Jun 2026 · 10 likes Confirming post #13 from a second method, which matters more than confirming it from a second person. Worth stating the null on HbA1c lag before we explain it: the…
Submitting a sample: the process end to end Replied, post #38 · Sourcing › Independent verification · 25 Jun 2026 · 0 likes If you are new and reading this thread for the answer to submitting a sample: the answer is conditional, the conditions are in the third reply, and the rest of the…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #45 · Compounds › Repair & healing peptides · 20 Jun 2026 · 0 likes Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #30 · Pharmacology › Formulation chemistry · 10 Jun 2026 · 3 likes Solubility limits looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
When a dose reduction is the correct response to a side effect Replied, post #28 · Practice › Dosing & titration · 10 Jun 2026 · 0 likes Post #24 and I disagree about the size of the effect, not about the direction. Reaching a dose and staying there for a year: the question of whether a stable dose…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #55 · Meta › Announcements · 29 May 2026 · 16 likes Adding a null result on Trust level 3 requirements. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #32 · Compounds › Tirzepatide · 8 May 2026 · 0 likes Post #30 describes the usual case. This is about the unusual one. SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological…
Micro-titration: a disputed topic, argued properly Replied, post #69 · Practice › Dosing & titration · 4 May 2026 · 2 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
Follow-up: State-level differences that actually matter Replied, post #41 · Regional › North America · 6 Apr 2026 · 10 likes Prior authorisation criteria are usually published by the payer and reading them before the appointment changes the outcome more than anything else does. Written in the…
Pregnancy and pregnancy planning: contraindication and washout Replied, post #60 · Clinical › Special populations · 3 Mar 2026 · 0 likes I have no financial interest in anything named in this thread and I want to say so before I comment on pregnancy and pregnancy planning, because it is the sort of…
Personal import allowances, compared — a second dataset Replied, post #74 · Access › International · 24 Feb 2026 · 0 likes Everything in post #73 holds. The case it does not cover is the one I have. Temperature-controlled material and long-haul travel is a practical problem with practical…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #7 · Meta › Announcements · 19 Feb 2026 · 4 likes Adding a data point of agreement rather than a data point.
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #71 · Outcomes › Progress reports · 17 Feb 2026 · 7 likes Everything in post #69 holds. The case it does not cover is the one I have. Two things can be true about Seven-day rolling at once: the mechanism is plausible and the…
[2026 update] Publication patterns in the BPC-157 literature, examined Replied, post #10 · Compounds › Repair & healing peptides · 12 Feb 2026 · 30 likes This follows post #9 rather than contradicting it. Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #90 · Clinical › Special populations · 1 Feb 2026 · 0 likes Adding the measurement that post #89 says would settle it. Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many…
Why semaglutide solutions can look faintly opalescent and when that matters Replied, post #62 · Compounds › Semaglutide · 1 Feb 2026 · 27 likes What I can speak to on semaglutide solutions is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #90 · Clinical › Special populations · 25 Jan 2026 · 0 likes Second-hand on Pregnancy and pregnancy planning, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #71 · Access › Pricing · 25 Jan 2026 · 6 likes My understanding of Price changes is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #56 · Analytics › Method validation · 18 Jan 2026 · 0 likes Post #55 answers the question as asked. The question underneath it is different. Robustness: the method gives consistent results when minor parameters vary. Tested by…
MHRA statements, read directly Replied, post #61 · Regional › UK & Ireland · 3 Jan 2026 · 10 likes Answering the question post #57 raises rather than the one it answers. I have no financial interest in anything named in this thread and I want to say so before I…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #43 · Clinical › Bloodwork · 3 Jan 2026 · 24 likes This follows post #41 rather than contradicting it. The number people quote for panel is a central estimate presented without its interval, and the interval is wide…
The most common factual error about semaglutide on the internet — what changed since Started this topic · Compounds › Semaglutide · 30 Dec 2025 · 13 likes The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Putting the…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #44 · Pharmacology › Pharmacokinetics · 24 Dec 2025 · 0 likes Confirming post #41 from a second method, which matters more than confirming it from a second person. Half-life determines how quickly concentration approaches steady…
Heterogeneity as information rather than as a nuisance Replied, post #25 · Evidence › Meta-analyses · 14 Dec 2025 · 0 likes Confirming post #22 from a second method, which matters more than confirming it from a second person. Study quality and weighting: some meta-analyses weight all studies…
Tracking a preprint to publication: a worked example Replied, post #90 · Evidence › Preprints · 9 Dec 2025 · 4 likes If you cite a preprint in a maintained document here, the convention is to label it in the sentence and to note the check date. The document review will catch the…
Tracking that stops updating and then resumes — the long version Replied, post #46 · Sourcing › Logistics · 3 Dec 2025 · 32 likes Tracking accuracy at each hop is a reasonable proxy for how much attention the shipment is getting, and it costs nothing to note.
Coverage in the US: a map of the usual obstacles Replied, post #17 · Regional › North America · 1 Dec 2025 · 8 likes What I would want before treating coverage as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Thyroid function tests during substantial weight change Replied, post #142 · Clinical › Bloodwork · 20 Nov 2025 · 3 likes Fasting state: some lab tests require fasting; others do not. Lipids on a fasting draw differ from lipids on a fed draw. Always note whether the test was fasting when…
[2026 update] What steady state means for the decision to escalate Replied, post #82 · Practice › Dosing & titration · 13 Nov 2025 · 23 likes The arithmetic in post #81 is right; the assumption feeding it is the part to check. An honest declaration on steady state: I have a prior here and it is strong enough…
Second pass at: The mass-error checker and its intended scope Replied, post #49 · Data & Tools › Calculators · 28 Oct 2025 · 8 likes The useful distinction on mass-error checker is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #58 · Pharmacology › Receptor biology · 27 Oct 2025 · 11 likes GIP receptor biology is genuinely contested. Both agonism and antagonism have been argued to produce weight reduction, and the fact that the field can hold both…
What pooling buys you and what it destroys Replied, post #38 · Evidence › Meta-analyses · 9 Oct 2025 · 0 likes Post #37 put the caveat in the right place and I want to underline it. Pooling buys has a well-known answer and a correct answer, and the interesting work is…
What a purity-only report leaves out Replied, post #33 · Sourcing › Independent verification · 3 Oct 2025 · 15 likes It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about anything other than what was measured. This is where my knowledge…
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #43 · Analytics › Method validation · 11 Sep 2025 · 10 likes The arithmetic in post #40 is right; the assumption feeding it is the part to check. Offering a way to settle LOD and LOQ rather than another opinion about it. Two…
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #50 · Practice › Reconstitution · 1 Sep 2025 · 0 likes Confirming post #47 from a second method, which matters more than confirming it from a second person. Dead volume is the part nobody mentions until it costs them a…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #106 · Compounds › Tirzepatide · 15 Aug 2025 · 0 likes I had written a reply contradicting post #105 and deleted it. Here is what survived. Reading this GIP component of tirzepatide thread as someone who came in with a…
Travel coolers and how long they really hold Replied, post #83 · Devices › Cold chain · 8 Aug 2025 · 15 likes Adding the measurement that post #82 says would settle it. One more thing on travel coolers that took me far too long to see: the two figures people quote are not…
Revisiting: List price versus negotiated price versus what you pay Replied, post #7 · Access › Pricing · 4 Aug 2025 · 0 likes The number people quote for List price versus negotiated price is a central estimate presented without its interval, and the interval is wide enough that the estimate…
When a preprint is the best available evidence and we say so Replied, post #15 · Evidence › Preprints · 1 Aug 2025 · 11 likes Peer review catches some things reliably — missing methods, unsupported conclusions, statistical mistakes of the obvious kind — and misses others routinely. Knowing…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #89 · Compounds › Tirzepatide · 17 Jul 2025 · 0 likes Adding a reference point for GIP component of tirzepatide. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be…
"Should I double up?" — answered once, at length, calmly Replied, post #5 · Practice › Administration · 4 Jul 2025 · 11 likes Drawing up with one needle and injecting with another: a reasonable practice if you have extra needles. Fresh needle for injection reduces tissue drag and can decrease…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #55 · Evidence › Journal club · 21 Jun 2025 · 26 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
Repeatability versus intermediate precision Replied, post #25 · Analytics › Method validation · 20 Jun 2025 · 2 likes Answering the question post #23 raises rather than the one it answers. The limit of quantitation determines what the impurity table can honestly contain. Peaks below it…
Reconstituting a multi-strength kit without mixing yourself up Replied, post #88 · Practice › Reconstitution · 20 Jun 2025 · 0 likes Having read the whole reconstituting a multi-strength kit thread before replying: the question in the first post has not actually been answered yet, and three of us…
A claim built entirely on a subgroup analysis Replied, post #51 · Evidence › Study critique · 23 May 2025 · 10 likes Reading rather than contributing, but this is the most useful thread I have found on it.
Second pass at: Designing a personal experiment that could change your mind Replied, post #13 · Research Methods › N-of-1 designs · 17 May 2025 · 27 likes Where I would push back on the Designing a personal experiment consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #91 · Sourcing › Independent verification · 14 May 2025 · 0 likes I have been on both sides of the Janoshik argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
A report I filed that turned out to be wrong, and the correction Replied, post #41 · Sourcing › Vendor reports · 6 May 2025 · 23 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
A supplier that answers analytical questions with restated claims Replied, post #70 · Sourcing › Red flags · 5 May 2025 · 6 likes Adding a reference point for supplier. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Reconstituting a multi-strength kit without mixing yourself up Replied, post #63 · Practice › Reconstitution · 27 Apr 2025 · 11 likes Reading back through, this was answered upthread and I missed it. My fault.
When to stop reading forums, including this one — the long version Replied, post #2 · Wellbeing › Mental health · 25 Apr 2025 · 4 likes The opening post and I disagree about the size of the effect, not about the direction. Expectations set by other people's reported trajectories are a documented source…
Validating a calculator against hand arithmetic — what changed since Replied, post #17 · Data & Tools › Calculators · 15 Apr 2025 · 28 likes The documentation on Validating a calculator against hand is better than this thread and I say that as someone who has posted in the thread.
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #42 · Compounds › Secretagogues & GH axis · 13 Apr 2025 · 4 likes Post #38 and I disagree about the size of the effect, not about the direction. Injection-site reactions are reported more often in this family than for the incretins.…
When "no data" is the complete and final answer Replied, post #137 · Compounds › Other compounds · 3 Apr 2025 · 5 likes The arithmetic in post #136 is right; the assumption feeding it is the part to check. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real…
Why cagrilintide alone is discussed so much less than in combination Replied, post #79 · Compounds › Cagrilintide & amylin analogues · 1 Apr 2025 · 0 likes Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin…
Validating a method you did not develop — does this still hold? Replied, post #137 · Analytics › Method validation · 19 Mar 2025 · 1 like Worth separating two things that post #135 runs together. A method that reports the same number for every lot is worth a second look. Real processes vary, and a total…
Retatrutide dose escalation in the published trials Replied, post #25 · Compounds › Retatrutide · 18 Mar 2025 · 2 likes Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #48 · Sourcing › Vendor reports · 16 Mar 2025 · 10 likes Reports of ordinary results are more valuable than reports of remarkable ones, precisely because only the remarkable ones get posted elsewhere.
UK access routes, dated and sourced — a second dataset Replied, post #42 · Regional › UK & Ireland · 23 Feb 2025 · 0 likes Anyone quoting an eligibility threshold should say which document it comes from. The thresholds have changed and the old ones are still circulating. I would call that…
A promotion I argued against, and why I lost Replied, post #75 · Documentation › Doc review · 26 Jan 2025 · 0 likes Worth separating two things that post #71 runs together. The number people quote for promotion is a central estimate presented without its interval, and the interval is…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #51 · Compounds › Cagrilintide & amylin analogues · 16 Jan 2025 · 33 likes Post #48 answers the question as asked. The question underneath it is different. Summarising the amylin analogue mechanism thread so far, since it is long and the…
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #5 · Clinical › Bloodwork · 31 Dec 2024 · 0 likes Whatever the answer on Lipid changes during rapid weight turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public,…
Why we hide unevidenced fraud accusations and log the hiding Replied, post #27 · Sourcing › Red flags · 16 Dec 2024 · 11 likes Building on post #25 rather than restating it. The most useful contribution to this subcategory is a resolved case written up with the resolution, because the…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #58 · Evidence › Journal club · 12 Dec 2024 · 0 likes Worth separating two things that post #56 runs together. Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then…
Revisiting: Moderation log format change Replied, post #42 · Meta › Announcements · 26 Nov 2024 · 3 likes Narrowing post #40, because the general version has more than one answer. Implementation timeline: announcements include when a change takes effect. Marking the date…
EMA product information as a primary source — does this still hold? Replied, post #25 · Regional › European Union · 15 Nov 2024 · 0 likes Nothing here is medical or legal advice, and this subcategory in particular attracts questions where that matters. I am reporting what happened, not recommending it.
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #59 · Compounds › Repair & healing peptides · 15 Nov 2024 · 30 likes Post #55 and I disagree about the size of the effect, not about the direction. Reading a preclinical wound-healing model: the model shows whether a mechanism is…
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #21 · Sourcing › Regulatory · 5 Nov 2024 · 31 likes I would call the community position on Research-use-only labelling likely rather than established, and I would be comfortable defending that hedge.
How to ask for a dose change without antagonising anyone — what changed since Replied, post #28 · Clinical › Prescriber conversations · 3 Nov 2024 · 16 likes Questions about dose: asking "how will we determine whether this dose is working for me" gets at the monitoring plan. Asking "can we start lower" or "can we escalate…
A vial that will not fully dissolve: what to check and in what order Replied, post #3 · Practice › Reconstitution · 16 Sep 2024 · 29 likes A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some preservatives crystallise in cold), is the vial being warmed gently…
Promotion criteria, and the one that stops most nominations Replied, post #62 · Documentation › Doc review · 15 Sep 2024 · 0 likes I would keep promotion criteria and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them…
When a red flag was a misunderstanding, and the retraction Replied, post #16 · Sourcing › Red flags · 13 Sep 2024 · 13 likes Understood, and I withdraw the assumption I opened with.
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #19 · Clinical › Bloodwork · 9 Sep 2024 · 7 likes Two things can be true about bring a laboratory at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is…
Cold packs, phase-change material, and what survives ten days Replied, post #122 · Sourcing › Logistics · 19 Jul 2024 · 20 likes Where I part company with post #118, and it is a narrow parting. Two claims get bundled together under cold packs and they need separating. The descriptive one — this…
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #83 · Practice › Dosing & titration · 9 Jul 2024 · 23 likes Research-use-only material is not a licensed product and no labelling covers it. Everything in this subcategory about published schedules describes what was done in…